Fabric Genomics, a California-based global leader in clinical interpretation of genomic data, and Genomenon, an Ann Arbor company specializing in genomic data search, Thursday announced they have entered into a partnership to strengthen clinical genomic interpretation and variant classification.
The agreement will allow the companies to integrate and co-market their solutions. Fabric Genomics combines artificial intelligence algorithms with automated workflows to speed and scale genomic interpretation. Genomenon’s literature search engine facilitates literature review for accurate interpretation.
“We’re so pleased to join with Fabric Genomics in the effort to reduce the time needed to detect the cause of genetic illnesses that can be life-threatening,” says Mike Klein, CEO of Genomenon. “By increasing specificity and sensitivity, reducing false negatives, and saving valuable time, our search engine is enhancing the adoption of precision medicine as the gold standard. Fabric’s leadership in genomic interpretation makes them the perfect partner in the effort to achieve that goal.”
Fabric Genomics’ Fabric Enterprise allows hospitals and labs the ability to maximize their diagnostic yield and optimize turnaround time. It starts with raw-sequence data from whole genome, exome, or targeted panels and provides workflows for analyzing, interpreting, and signing off physician-ready reports.
Its automated scoring and classification system allows easy adoption of American College of Medical Genetics (ACMG) standards and accelerates interpretation with a step-wise, guided assessment of each ACMG criterion.
Genomenon’s Mastermind Genomic Search Engine filters and prioritizes millions of genomic articles for the most useful and meaningful citations, saving scientists search time when they find a variant that is not easily classified. Easy and reliable searches can be critical for diagnosis.
“Combining Fabric’s algorithmic genomic analysis with Genomenon’s literature search further enhances our approach to scaling genomic interpretation,” says Martin G. Reese, president and CEO of Fabric Genomics. “Fabric is committed to providing users with fast and accurate means of identifying clinically actionable variants that can provide a clear patient diagnosis. Integrating Mastermind within our interpretation platform will help our users minimize the manual effort it takes to select and read relevant evidence-based papers.”
